Prostate Cancer Treatment Might Help Some Glioblastoma Patients

Anti-androgen therapy showed positive results in cell lines and animal models.

11:06 AM

Author | Ian Demsky

drawing of cancer cells
Image by Stephanie King.

Anti-androgens are known to increase the effectiveness of radiation therapy for prostate cancer patients, helping to slow the rate at which the cancer can repair DNA damage caused by the treatment.

Could the same strategy work against glioblastoma, an aggressive brain cancer that quickly grows resistant to radiation?

Research led by the University of Michigan Rogel Cancer Center showed promising results in laboratory models.

The team's findings, which appear in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, showed that several antiandrogen medicines slowed the growth of glioblastoma and made it more sensitive to radiation treatment in cell lines and patient-derived xenograft models.

"These results are very encouraging," says senior study author Daniel Wahl, M.D., Ph.D., a radiation oncologist and researcher at U-M. "And they may help shed light on differences seen in men and women — Men are slightly more likely to develop GBM and women have slightly better outcomes. This may be due to higher levels of circulating testosterone, and thus higher levels of androgen receptor signaling, in men."

Anti-androgens are also able to cross the blood-brain barrier, which is key property for potential drugs used to treat brain cancer.

About half of glioblastoma patients showed activity of their androgen receptors at levels similar to those seen in prostate cancer patients, indicating antiandrogen treatment might be helpful to a large subset of patients.

Paper cited: "Expression of the of the androgen receptor governs radiation resistance in a subset of glioblastomas vulnerable to anti-androgen therapy," Molecular Cancer Therapeutics. DOI: 10.1158/1535-7163.MCT-20-0095

More Articles About: Lab Notes Brain Cancer Cancer Research Cancer: Cancer Types
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories Glioma stains red blue green
Health Lab
New Treatment Approach for a Common Glioma Subtype Shows Promise in Animal Models
A combination approach, which included metabolic reprogramming and immunotherapy, led to complete tumor regression in 60% of study mice.
Health Lab
"Drawing Dad" becomes sensation throughout pediatric cancer unit
A form of art therapy for one dad brings joy to patients across his child's floor, also in-patient receiving treatments.
liver in bright green against navy background
Health Lab
Genetic variation with MASLD reveals subtypes and potential therapeutic avenues
A Michigan Medicine team of experts seeks to identify the human genetic causes of MASLD, formerly called NAFLD
cancer cell
Health Lab
Language barriers in cancer care
Research from experts at Michigan Medicine shows that significant language-based disparities exist in patients’ access to cancer care services, and it’s well before their first appointment with a doctor. 
blood sample
Health Lab
Early findings suggest clinical and lab-based approach critical to tracking head and neck cancer recurrence
Early findings of two studies from the University of Michigan Rogel Cancer Center shed light on new ways to anticipate recurrence in HPV-positive head and neck cancer sooner. The papers, published in Cancer and Oral Oncology, offer clinical and technological perspectives on how to measure if recurrence is happening earlier than current blood tests allow, and provide a framework for a new, more sensitive blood test that could help in this monitoring.
nanoparticles floating green blue
Health Lab
Gene therapy for brain tumor shows promising early results in humans
Research from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer.